Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.54 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.54 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.41 |
| ▸ | KDM4A | O75164 | 4/20 | 0.56 |
| ▸ | KDM2A | Q9Y2K7 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ALPG | P10696 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.54 |
| ▸ | INSR | P06213 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL28531710 | 1.00 | KDM4A (0.56) | KDM4AKDM2AALDH1A1MEN1LMNA | |
| Iodide SCHEMBL187218 | 1.00 | KDM4A (0.56) | KDM4AKDM2AALDH1A1MEN1LMNA | |
| Iodide SCHEMBL592580 | 1.00 | KDM4A (0.56) | KDM4AKDM2AALDH1A1MEN1LMNA | |
| Iodide SCHEMBL554665 | 1.00 | KDM4A (0.56) | KDM4AKDM2AALDH1A1MEN1LMNA | |
| Iodide SCHEMBL21494443 | 1.00 | KDM4A (0.56) | KDM4AKDM2AALDH1A1MEN1LMNA | |
| Iodide SCHEMBL3954408 | 1.00 | KDM4A (0.56) | KDM4AKDM2AALDH1A1MEN1LMNA | |
| Iodide SCHEMBL3954410 | 1.00 | KDM4A (0.56) | KDM4AKDM2AALDH1A1MEN1LMNA | |
| Iodide SCHEMBL28531712 | 1.00 | KDM4A (0.56) | KDM4AKDM2AALDH1A1MEN1LMNA | |
| Iodide SCHEMBL187217 | 1.00 | KDM4A (0.56) | KDM4AKDM2AALDH1A1MEN1LMNA | |
| Hydrochloric Acid SCHEMBL4634452 | 0.99 | KDM4A (0.55) | KDM4AKDM2AALDH1A1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970325-B1 | LYSOPHOSPHATIDIC ACID DETECTION | UNIV PORTLAND STATE (US) | 2017-09-27 | — | — | EP | claimed |
| US-20160047830-A1 | LYSOPHOSPHATIDIC ACID DETECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-18 | — | — | US | claimed |
| EP-2970325-A2 | LYSOPHOSPHATIDIC ACID DETECTION | Portland State University (US) | 2016-01-20 | — | — | EP | claimed |
| US-20150301058-A1 | BIOMARKER COMPOSITIONS AND METHODS | CARIS LIFE SCIENCES SWITZERLAND HOLDINGS GMBH (CH) | 2015-10-22 | — | — | US | claimed |
| EP-2922861-A1 | BIOMARKER COMPOSITIONS AND METHODS | Caris Science Inc. (US) | 2015-09-30 | — | — | EP | claimed |
| WO-2014144561-A2 | LYSOPHOSPHATIDIC ACID DETECTION | THE OREGON STATE BOARD OF HIGHER EDUCATION ACTING BY AND THROUGH PORTLAND STATE UNIVERSITY (US) | 2014-09-18 | — | — | WO | claimed |
| WO-2014082083-A1 | BIOMARKER COMPOSITIONS AND METHODS | CARIS SCIENCE, INC. (US) | 2014-05-30 | — | — | WO | claimed |
| US-20090204057-A1 | METHOD AND DEVICE FOR PHOTODYNAMIC THERAPY | QUEST PHARMATECH INC. (CA) | 2009-08-13 | — | — | US | claimed |
| WO-2008011707-A1 | METHOD AND DEVICE FOR PHOTODYNAMIC THERAPY | QUEST PHARMATECH INC. (CA) | 2008-01-31 | — | — | WO | claimed |
| EP-1039834-B1 | OPTOACOUSTIC CONTRAST AGENTS AND METHODS FOR THEIR USE | IMARX PHARMACEUTICAL CORP (US) | 2005-09-28 | — | — | EP | claimed |
| EP-1039834-A4 | OPTOACOUSTIC CONTRAST AGENTS AND METHODS FOR THEIR USE | IMARX PHARMACEUTICAL CORP (US) | 2001-12-05 | — | — | EP | claimed |
| EP-1039834-A1 | OPTOACOUSTIC CONTRAST AGENTS AND METHODS FOR THEIR USE | IMARX PHARMACEUTICAL CORP. (US) | 2000-10-04 | — | — | EP | claimed |
| US-6123923-A | ADMINISTERING A PATIENT A CONTRAST AGENT CONTAINING A STABILIZER, A PHOTOACTIVE AGENT, A GASEOUS PRECURSOR SUCH AS PERFLUORINATED COMPOUND OR GAS OR BOTH, AND SCANNING THE PATIENT USING ULTRASOUND IMAGING AND OPTICAL IMAGING | IMARX PHARMACEUTICAL CORP. (US) | 2000-09-26 | — | — | US | claimed |
| WO-1999030620-A1 | OPTOACOUSTIC CONTRAST AGENTS AND METHODS FOR THEIR USE | IMARX PHARMACEUTICAL CORP. (US) | 1999-06-24 | — | — | WO | claimed |
| EP-4746852-A1 | LIPID AGGREGATES FOR INTRAARTICULAR ADMINISTRATION | Universität Bern (CH) | 2026-05-27 | — | — | EP | disclosed |
| CN-121586573-A | Lipopolymers for intra-articular administration | 伯尔尼大学 | 2026-02-27 | — | — | CN | disclosed |
| EP-3256850-B1 | HYDROGEL PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME | SLINGSHOT BIOSCIENCES INC (US) | 2025-07-09 | — | — | EP | disclosed |
| EP-0759162-A1 | STRUCTURES WITH FIELD RESPONSIVE PERMEATION CONTROL | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, URBANA-CHAMPAIGN (US) | 1997-02-26 | — | — | EP | disclosed |
| US-5556528-A | Structures with field responsive permeation control | BIOTECHNOLOGY RESEARCH & DEVELOPMENT CORPORATION (US) | 1996-09-17 | — | — | US | disclosed |
| WO-1995030892-A1 | STRUCTURES WITH FIELD RESPONSIVE PERMEATION CONTROL | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, URBANA-CHAMPAIGN (US) | 1995-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160047830-A1 | LYSOPHOSPHATIDIC ACID DETECTION | LPAR6, LPAR1, LPAR2 | CHRM1 1517/4885CHRM3 1090/4885ACHE 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.